喘可治注射液对慢性阻塞性肺疾病患者呼吸困难程度和运动耐力的影响  

Effects of Chuankezhi Injection on Dyspnea Severity and Exercise Tolerance in Patients with COPD

作　　者：黄小华[1] 洪敏俐[1] 陈文喜[1] 高凌云[1] 洪春霖[2] 郑伟彬[1] 刘燕鸿[3] 

机构地区：[1]福建中医药大学附属漳州市中医院呼吸科,福建漳州363000 [2]福建中医药大学附属漳州市中医院检验科,福建漳州363000 [3]福建中医药大学,福建福州350013

出　　处：《辽宁中医药大学学报》2012年第11期51-53,共3页Journal of Liaoning University of Traditional Chinese Medicine

基　　金：福建省医学创新课题(2009-CXB-42)

摘　　要：目的:观察喘可治注射液中药制剂对脾肾阳虚型慢性阻塞性肺疾病(COPD)稳定期患者呼吸困难程度和运动耐力的影响。方法:将60例中医辨证属脾肾阳虚的稳定期COPD患者随机分为治疗组(30例)和对照组(30例)。对照组给予西医常规方案治疗,治疗组在西医常规方案治疗基础上加用喘可治注射液,疗程均为3个月。采用改良的英国医学研究委员会呼吸困难量表评分(MMRC)和6分钟步行距离(6MWD)指标观察两组患者治疗前后呼吸困难程度和运动耐力的变化。结果 :经3个月治疗,两组患者治疗后的MMRC与治疗前比较均有下降,差异具有显著性(P<0.01),但治疗组下降更明显,与对照组比较差异具有显著性(P<0.05)。两组患者治疗后6MWD均较治疗前改善,治疗组从(364.93±46.49)m增加到(394.19±49.03)m(P<0.01),对照组从(346.31±57.75)m增加到(363.31±48.30)m(P<0.05),治疗组6MWD增加更明显,与对照组比较差异具有显著性(P<0.05)。结论:喘可治注射液可以减轻脾肾阳虚型COPD稳定期患者呼吸困难,提高患者的运动耐力,从而改善患者的生活质量。Objective：To evaluate the effects of Chuankezhi Injection on dyspnea severity,exercise tolerance in patients with chronic obstructive pulmonary disease（COPD）.Methods：60 patients with COPD at the stable phase who met the traditional Chinese medicine syndrome differentiation criteria of spleen and kidney yang deficiency were enrolled.The patients were randomly divided into two groups（therapeutic group 30 cases and control group 30 cases,respectively）.The therapeutic group was treated by Chuankezhi Injection combined with conventional therapy while the control group was treated with conventional therapy only.The modified medical research council（MMRC）dyspnea scale and 6-minute walk distance（6MWD）were recorded to evaluate the difference of dyspnea severity and exercise tolerance before and after treatment in patients with COPD.Results：MMRC in both groups decreased significantly after 3 months treatment compared with baseline（P0.01,respectively）.But it dropped significantly in therapeutic group than that in control group 3 months later（P0.05）.6MWD significantly improved after 3 months treatment compared with baseline,from（364.93±46.49）m to（394.19±49.03）m（P0.01）in therapeutic group and from（346.31±57.75）m to（363.31±48.30）m in control group（P0.05,respectively）.The improvement of 6MWD was greater in therapeutic group than that in control group 3 months later（P0.05）.Conclusion：The results indicated that Chuankezhi Injection could relieve dyspnea severity,enhance patients＇ exercise endurance,improve the quality of life with COPD（spleen and kidney yang deficiency）in stable phase.

关 键 词：慢性阻塞性肺疾病 喘可治注射液 MMRC 6MWD 

分 类 号：R563[医药卫生—呼吸系统]